Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trulieve Cannabis Corp C.TRUL

Alternate Symbol(s):  TCNNF | C.TRUL.NT.U

Trulieve Cannabis Corp. is a vertically integrated cannabis company. The Company has established cannabis operations in three hubs: Southeast, Northeast, and Southwest. Its three regional hubs are anchored by market positions in cornerstone states of Florida, Pennsylvania, and Arizona. The Company operates in regulated markets that require knowledge in cultivation, manufacturing, and retail. The Company utilizes various extraction techniques, including critical ethanol extraction, carbon dioxide extraction, hydrocarbon extraction, and mechanical separation. In addition, the Company owns and utilizes carbon dioxide extraction, distillation, purification and manufacturing technology that is used to produce a range of cannabis topicals and vapes featuring cannabinoids. The Company's brands include premium tier brands Avenue, Cultivar Collection, and Muse; mid-tier brands Modern Flower, Alchemy, Momenta, and Sweet Talk, and value tier brands Co2lors, Loveli, Roll One, and Trekkers.


CSE:TRUL - Post by User

Bullboard Posts
Comment by ipanemaon Jul 06, 2019 8:31am
77 Views
Post# 29891904

RE:Form 7

RE:Form 7Hi Snapback, just to complement your thorough summary with reference to the June  Form 7 and to your sales forecast. Last quarter I took the simle avergae of the 3 months (Jan to March) of patients end of month and multiplied by the average quarterley sales per patient in Q4 of $325.37 in the quarter. That gave me a total forecast for Q1 of $44.8m or 0.7% over the actual revenues. If I do the same again using the actual av sales per patient in Q1 of $322.96 I get $54.8m. But this Q2 we have flower for the whole Q less some cannabilization of existing products, as per KR during the Q1 results announcement interview, so I'm forecasting between $56.5m and $59m. We should know within 6 weeks or so. Not nearly as conservative as you! GLTA.

Bullboard Posts